Investing.com - Biogen (NASDAQ:BIIB) reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Biogen announced earnings per share of $3.62 on revenue of $2.53B. Analysts polled by Investing.com anticipated EPS of $4.34 on revenue of $2.5B.
Biogen shares are down 13% from the beginning of the year and are trading at $207.32 , down-from-52-week-high.They are broadly in line with the S&P 500 which is down 12.82% from the start of the year.
Biogen follows other major Healthcare sector earnings this month
Biogen's report follows an earnings beat by UnitedHealth on Thursday, April 14, 2022, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on Tuesday, April 19, 2022 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar